PAI-1, progress in understanding the clinical problem and its aetiology
- PMID: 22360729
- DOI: 10.1111/j.1365-2141.2012.09074.x
PAI-1, progress in understanding the clinical problem and its aetiology
Abstract
Plasminogen activator inhibitor-1 (PAI-1, also known as SERPINE1) is a member of the serine protease inhibitor (SERPIN) superfamily and is the primary physiological regulator of urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) activity. Although the principal function of PAI-1 is the inhibition of fibrinolysis, PAI-1 possesses pleiotropic functions besides haemostasis. In the quarter century since its discovery, a number of studies have focused on improving our understanding of PAI-1 functions in vivo and in vitro. The use of Serpine1-deficient mice has particularly enhanced our understanding of the functions of PAI-1 in various physiological and pathophysiological conditions. In this review, the results of recent studies on PAI-1 and its role in clinical conditions are discussed.
© 2012 Blackwell Publishing Ltd.
Similar articles
-
Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.Blood Coagul Fibrinolysis. 1994 Feb;5(1):73-81. Blood Coagul Fibrinolysis. 1994. PMID: 8180342 Review.
-
Use of mouse models to study plasminogen activator inhibitor-1.Methods Enzymol. 2011;499:77-104. doi: 10.1016/B978-0-12-386471-0.00005-5. Methods Enzymol. 2011. PMID: 21683250
-
The role of fibrinolytic genes and proteins in the development of allograft vascular disease.J Heart Lung Transplant. 2011 Aug;30(8):935-44. doi: 10.1016/j.healun.2011.04.002. Epub 2011 Jun 8. J Heart Lung Transplant. 2011. PMID: 21652221
-
The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.Biol Chem. 2002 Jan;383(1):21-36. doi: 10.1515/BC.2002.003. Biol Chem. 2002. PMID: 11928815 Review.
-
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.Cancer Res. 1994 May 15;54(10):2527-30. Cancer Res. 1994. PMID: 8168072
Cited by
-
Leptin links with plasminogen activator inhibitor-1 in human obesity: the SABPA study.Hypertens Res. 2015 Jul;38(7):507-12. doi: 10.1038/hr.2015.28. Epub 2015 Mar 5. Hypertens Res. 2015. PMID: 25740294
-
Association of glucose to lymphocyte ratio with the risk of death in patients with atherosclerotic cardiovascular disease.Sci Rep. 2025 Jan 31;15(1):3861. doi: 10.1038/s41598-025-87260-9. Sci Rep. 2025. PMID: 39890934 Free PMC article.
-
Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study.Crit Care. 2023 Feb 10;27(1):55. doi: 10.1186/s13054-023-04329-5. Crit Care. 2023. PMID: 36765421 Free PMC article.
-
Identification and validation of SERPINE1 as a prognostic and immunological biomarker in pan-cancer and in ccRCC.Front Pharmacol. 2023 Aug 23;14:1213891. doi: 10.3389/fphar.2023.1213891. eCollection 2023. Front Pharmacol. 2023. PMID: 37680718 Free PMC article.
-
The association between the metabolic score for insulin resistance and mortality in patients with cardiovascular disease: a national cohort study.Front Endocrinol (Lausanne). 2024 Dec 18;15:1479980. doi: 10.3389/fendo.2024.1479980. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39758345 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous